Human papillomavirus viral load: A possible marker for cervical disease in HIV-infected women

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 5, 2006, Pages 810-814

  Lillo, Flavia B ^a   Uberti Foppa, Caterina ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cervical cancer; Prevention; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; MESSENGER RNA; VIRUS RNA; WART VIRUS VACCINE;

CANCER PREVENTION; CANCER RISK; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; EDITORIAL; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INCIDENCE; INFECTION RISK; LABORATORY DIAGNOSIS; LIPODYSTROPHY; METABOLIC DISORDER; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRUS CARCINOGENESIS; VIRUS DIAGNOSIS; VIRUS DNA CELL DNA INTERACTION; VIRUS EXPRESSION; VIRUS LOAD; VIRUS TYPING; WART VIRUS;

BIOLOGICAL MARKERS; CERVIX UTERI; FEMALE; HIV INFECTIONS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; UTERINE CERVICAL DISEASES; VAGINAL SMEARS; VIRAL LOAD;

EID: 33645802379     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl073     Document Type: Editorial

References (32)

1. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F55-78.
2. Uberti-Foppa C, Origoni M, Maillard M et al. Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women. J Med Virol 1998; 56: 133-7.
3. Uberti-Foppa C, Ferrari D, Lodini S et al. Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. AIDS 2003; 17: 2136-8.
4. Lillo FB, Lodini S, Ferrari D et al. Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. Clin Infect Dis 2005; 40: 451-7.
5. Lillo FB, Ferrari D, Veglia F et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: Effect of highly active antiretroviral therapy. J Infect Dis 2001; 184: 547-51.
6. Schiffman M, Herrero R, Desalle R et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84.
7. Fontaine J, Hankins C, Mayrand MH et al. High levels of HPV-16 DNA are associated with high-grade cervical lesions in women at risk or infected with HIV. AIDS 2005; 19: 785-94.
8. Josefsson AM, Magnusson PK, Ylitalo N et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study. Lancet 2000; 355: 2189-93.
9. Lefevre J, Hankins C, Money D et al. Human papillomavirus type 16 viral load is higher in human immunodeficiency virus-seropositive women with high-grade squamous intraepithelial lesions than in those with normal cytology smears. J Clin Microbiol 2004; 42: 2212-15.
10. van Duin M, Snijders PJ, Schrijnemakers HF et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/ III and viral clearance. Int J Cancer 2002; 98: 590-5.
11. Ylitalo N, Sorensen P, Josefsson AM et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 2000; 355: 2194-8.
12. Monnier-Benoit S, Dalstein V, Riethmuller D. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 2006; 35: 270-7.
13. Flores R, Papenfuss M, Klimecki WT et al. Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia. Int J Cancer 2006; 118: 1187-93.
14. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004; 112: 854-9.
15. Dalstein V, Riethmuller D, Pretet JL et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: A longitudinal French cohort study. Int J Cancer 2003; 106: 396-403.
16. Hernandez-Hernandez DM, Ornelas-Bernal L, Guido-Jimenez Mrgas M et al. Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women. Gynecol Oncol 2003; 90: 310-17.
17. Sun CA, Liu JF, Wu DM et al. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet 2002; 76: 41-7.
18. Weissenborn SJ, Funke AM, Hellmich M et al. Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated. J Clin Microbiol 2003; 41: 2763-7.
19. Sherman ME, Schiffman M, Cox JT et al. Effects of age and human papilloma viral load on colposcopy triage: Data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2002; 94: 102-7.
20. Ordi J, Alonso I, Torne A et al. Human papillomavirus load in Hybrid Capture II assay: Does increasing the cutoff improve the test? Gynecol Oncol 2005; 99: 313-9.
21. Bigras G, de Marval F. The probability for a PAP test to be abnormal is directly proportional to HPV viral load: Results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer 2005; 93: 575-81.
22. Moscicki AB, Ellenberg JH, Crowley-Nowick P. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004; 190: 1413-21.
23. Heard I, Tassie JM, Schmitz V et al. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol 2000; 96: 403-9.
24. Moberg M, Gustavsson I, Wilander E et al. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005; 92: 891-4.
25. Andersson S, Safari H, Mints M et al. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer 2005; 92: 2195-200.
26. Sun CA, Lai HC, Chang CC et al. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol 2001; 83: 95-9.
27. Sherman ME, Wang SS, Wheeler CM et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: Dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003; 12: 1038-44.
28. Wright TC Jr, Cox JT, Massad LS et al. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: 2120-9.
29. Wright TC Jr, Cox JT, Massad LS et al. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol 2003; 189: 295-304.
30. Legood R, Gray A, Wolstenholme J. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: Results of the NHS pilot studies. BMJ 2006; 332: 79-85.
31. Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-32.
32. Frisch M, Biggar RJ, Engels EA et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285: 1736-45.